IO Biotech, Inc.

IOBTQ OTC SEC CIK 1865494
Follow IO Biotech Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2025 USD · US GAAP
Net income −$8.4M +65.1% vs same quarter last year
EPS, diluted −$0.13 +63.9% vs same quarter last year
Operating cash flow −$18.5M +11.2% vs same quarter last year
Operating income −$19.4M +27% vs same quarter last year
Net income by quarter
−$26.2M
−$19.5M
−$20.7M
−$24M
−$31.3M
−$22.4M
−$26.2M
−$8.4M
Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
−$100M−$75M−$50M−$25M$0FY19FY20FY21FY22FY23FY24
Show the numbers
YearNet income
FY24−$95.5M
FY23−$86.1M
FY22−$71.5M
FY21−$67.9M
FY20−$12M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY19FY20FY21FY22FY23FY24
Show the numbers
YearFree cash flow
FY24−$82.4M
FY23−$72.1M
FY22−$60.4M
FY21−$40.8M
FY20-
FY19-